Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (4874)	7/16/1998 6:09:00 PM
From: scaram(o)uche	Read Replies (1) of 6136

OK, let's return to this....... >> Later this month, we will reveal to the financial community an innovative plan to aggressively pursue development of these new HIV therapies, while maintaining steady growth of earnings in our VIRACEPT-driven anti-virals business in the current fiscal year. And we will describe our plan for continuing to pursue novel drugs for treatment of cancer and other serious diseases without loss of momentum. << This could be something like the recent BCHE move, spinning out R&D projects into a separate company, and giving that company to current shareholders as a dividend. Or..... it could be a slab of cash, a CHIR-like deal for something less than 50% of the company. Or, it could be a combination of the two, with a partner contributing funding to the R&D company. Any other ideas? Didn't someone mention "off balance sheet" recently? Rick

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next